| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis, Autoimmune | 23 | 2024 | 50 | 6.370 |
Why?
|
| Liver Cirrhosis, Biliary | 38 | 2024 | 87 | 5.700 |
Why?
|
| Hepacivirus | 42 | 2020 | 274 | 4.720 |
Why?
|
| Hepatitis C, Chronic | 33 | 2020 | 373 | 4.180 |
Why?
|
| Ribavirin | 30 | 2018 | 89 | 4.170 |
Why?
|
| Antiviral Agents | 41 | 2024 | 825 | 4.150 |
Why?
|
| Interferon-alpha | 26 | 2016 | 248 | 3.350 |
Why?
|
| Polyethylene Glycols | 23 | 2016 | 252 | 3.060 |
Why?
|
| Liver Transplantation | 53 | 2021 | 1127 | 2.840 |
Why?
|
| Proline | 15 | 2018 | 80 | 2.150 |
Why?
|
| Hepatitis C | 17 | 2017 | 389 | 2.090 |
Why?
|
| Hepatitis B | 19 | 2024 | 172 | 2.060 |
Why?
|
| Cholangitis, Sclerosing | 11 | 2025 | 74 | 1.980 |
Why?
|
| RNA, Viral | 26 | 2018 | 562 | 1.880 |
Why?
|
| Immunosuppressive Agents | 18 | 2024 | 693 | 1.850 |
Why?
|
| Cholangitis | 14 | 2025 | 39 | 1.780 |
Why?
|
| Liver Cirrhosis | 19 | 2024 | 933 | 1.730 |
Why?
|
| Hepatic Encephalopathy | 9 | 2016 | 88 | 1.410 |
Why?
|
| Imidazoles | 11 | 2020 | 217 | 1.210 |
Why?
|
| PPAR delta | 5 | 2024 | 10 | 1.200 |
Why?
|
| Hepatitis B virus | 13 | 2024 | 142 | 1.200 |
Why?
|
| Quinoxalines | 10 | 2020 | 40 | 1.140 |
Why?
|
| Liver | 38 | 2024 | 1875 | 1.130 |
Why?
|
| Chemical and Drug Induced Liver Injury | 9 | 2023 | 117 | 1.070 |
Why?
|
| Graft Rejection | 12 | 2020 | 628 | 1.070 |
Why?
|
| Chenodeoxycholic Acid | 2 | 2024 | 14 | 0.960 |
Why?
|
| Terminology as Topic | 9 | 2015 | 237 | 0.950 |
Why?
|
| Drug Therapy, Combination | 29 | 2018 | 1197 | 0.940 |
Why?
|
| Humans | 200 | 2025 | 133937 | 0.890 |
Why?
|
| Tissue and Organ Procurement | 9 | 2021 | 247 | 0.880 |
Why?
|
| Hepatitis | 6 | 2022 | 58 | 0.870 |
Why?
|
| Ursodeoxycholic Acid | 12 | 2024 | 38 | 0.860 |
Why?
|
| Sulfonamides | 12 | 2020 | 286 | 0.850 |
Why?
|
| Recombinant Proteins | 25 | 2016 | 1438 | 0.830 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2023 | 426 | 0.790 |
Why?
|
| Tissue Donors | 9 | 2021 | 525 | 0.730 |
Why?
|
| Viral Load | 13 | 2018 | 412 | 0.720 |
Why?
|
| Adult | 93 | 2025 | 31949 | 0.720 |
Why?
|
| Middle Aged | 85 | 2025 | 29409 | 0.720 |
Why?
|
| Genotype | 25 | 2020 | 2807 | 0.720 |
Why?
|
| Benzofurans | 5 | 2020 | 24 | 0.700 |
Why?
|
| Alkaline Phosphatase | 9 | 2024 | 104 | 0.680 |
Why?
|
| Liver Failure, Acute | 3 | 2011 | 96 | 0.680 |
Why?
|
| Carbamates | 14 | 2020 | 68 | 0.670 |
Why?
|
| Organ Transplantation | 2 | 2020 | 186 | 0.650 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 172 | 0.650 |
Why?
|
| Acetates | 5 | 2024 | 80 | 0.630 |
Why?
|
| Bile Ducts | 5 | 2011 | 54 | 0.610 |
Why?
|
| Ammonia | 2 | 2015 | 77 | 0.600 |
Why?
|
| Aged | 51 | 2024 | 21746 | 0.570 |
Why?
|
| Polymerase Chain Reaction | 9 | 2013 | 1629 | 0.570 |
Why?
|
| Cystatin C | 1 | 2018 | 66 | 0.550 |
Why?
|
| Graft vs Host Disease | 8 | 2011 | 623 | 0.550 |
Why?
|
| Autoimmune Diseases | 6 | 2019 | 279 | 0.550 |
Why?
|
| Male | 94 | 2025 | 65902 | 0.520 |
Why?
|
| Cholagogues and Choleretics | 7 | 2024 | 26 | 0.510 |
Why?
|
| Double-Blind Method | 17 | 2024 | 1667 | 0.510 |
Why?
|
| Female | 94 | 2025 | 71682 | 0.490 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 548 | 0.480 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 254 | 0.470 |
Why?
|
| DNA, Viral | 9 | 2015 | 499 | 0.470 |
Why?
|
| Automobile Driving | 1 | 2015 | 34 | 0.470 |
Why?
|
| Liability, Legal | 1 | 2015 | 50 | 0.470 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2011 | 247 | 0.450 |
Why?
|
| Cyclopropanes | 10 | 2020 | 70 | 0.450 |
Why?
|
| Virus Physiological Phenomena | 1 | 2014 | 15 | 0.430 |
Why?
|
| Drug Resistance, Viral | 7 | 2018 | 50 | 0.430 |
Why?
|
| Treatment Outcome | 34 | 2024 | 13013 | 0.420 |
Why?
|
| Gastrointestinal Agents | 2 | 2024 | 67 | 0.420 |
Why?
|
| Liver Failure | 4 | 2017 | 91 | 0.410 |
Why?
|
| Autoantibodies | 9 | 2018 | 466 | 0.400 |
Why?
|
| Chalcones | 2 | 2023 | 5 | 0.400 |
Why?
|
| Propionates | 2 | 2023 | 33 | 0.390 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 85 | 0.370 |
Why?
|
| Cognition Disorders | 1 | 2015 | 579 | 0.350 |
Why?
|
| Amides | 7 | 2020 | 86 | 0.350 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 34 | 0.350 |
Why?
|
| Mass Screening | 5 | 2019 | 834 | 0.350 |
Why?
|
| Young Adult | 22 | 2024 | 9889 | 0.350 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 3077 | 0.340 |
Why?
|
| Autoantigens | 1 | 2011 | 118 | 0.340 |
Why?
|
| Sofosbuvir | 4 | 2018 | 21 | 0.330 |
Why?
|
| Transplant Recipients | 3 | 2021 | 225 | 0.320 |
Why?
|
| HIV | 1 | 2011 | 195 | 0.320 |
Why?
|
| Drug Overdose | 3 | 2020 | 75 | 0.320 |
Why?
|
| Community Health Services | 1 | 2010 | 93 | 0.310 |
Why?
|
| Epithelial Cells | 4 | 2011 | 941 | 0.310 |
Why?
|
| Interferons | 6 | 2014 | 146 | 0.310 |
Why?
|
| Hypertension, Portal | 4 | 2014 | 81 | 0.310 |
Why?
|
| Hepatitis B, Chronic | 2 | 2007 | 86 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 1993 | 106 | 0.300 |
Why?
|
| Physicians | 1 | 2015 | 630 | 0.300 |
Why?
|
| Risk Factors | 18 | 2025 | 11100 | 0.300 |
Why?
|
| Oligopeptides | 3 | 2014 | 122 | 0.290 |
Why?
|
| Biopsy | 9 | 2024 | 1304 | 0.290 |
Why?
|
| Adolescent | 32 | 2023 | 20534 | 0.290 |
Why?
|
| Pruritus | 6 | 2024 | 43 | 0.290 |
Why?
|
| Viral Nonstructural Proteins | 5 | 2018 | 191 | 0.280 |
Why?
|
| Immunoglobulins | 4 | 2005 | 175 | 0.270 |
Why?
|
| Insulin Resistance | 1 | 2012 | 688 | 0.270 |
Why?
|
| Liver Diseases | 8 | 2007 | 390 | 0.260 |
Why?
|
| Retrospective Studies | 25 | 2025 | 17488 | 0.250 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1153 | 0.250 |
Why?
|
| Interleukins | 5 | 2014 | 132 | 0.250 |
Why?
|
| Referral and Consultation | 1 | 2010 | 571 | 0.250 |
Why?
|
| Patient Selection | 3 | 2020 | 734 | 0.250 |
Why?
|
| Cyclosporine | 5 | 2016 | 148 | 0.240 |
Why?
|
| Biliary Tract Diseases | 2 | 1999 | 37 | 0.240 |
Why?
|
| Cholestasis | 3 | 2023 | 158 | 0.240 |
Why?
|
| Virus Activation | 4 | 2024 | 85 | 0.240 |
Why?
|
| Isoquinolines | 2 | 2015 | 42 | 0.240 |
Why?
|
| Survival Analysis | 3 | 2007 | 1596 | 0.230 |
Why?
|
| PPAR alpha | 2 | 2023 | 54 | 0.230 |
Why?
|
| Biomarkers | 10 | 2023 | 3426 | 0.230 |
Why?
|
| Hepatitis B Antibodies | 6 | 2012 | 24 | 0.220 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2024 | 37 | 0.220 |
Why?
|
| Pyrrolidines | 7 | 2018 | 41 | 0.220 |
Why?
|
| Pharmacovigilance | 1 | 2024 | 11 | 0.220 |
Why?
|
| Recurrence | 10 | 2018 | 1471 | 0.220 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2024 | 85 | 0.220 |
Why?
|
| Living Donors | 5 | 2021 | 118 | 0.220 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2023 | 14 | 0.220 |
Why?
|
| Models, Statistical | 2 | 2017 | 505 | 0.220 |
Why?
|
| Iron Overload | 1 | 2023 | 16 | 0.210 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2024 | 66 | 0.210 |
Why?
|
| Hemochromatosis | 1 | 2023 | 37 | 0.210 |
Why?
|
| HIV Infections | 3 | 2018 | 2066 | 0.210 |
Why?
|
| Prognosis | 10 | 2020 | 5081 | 0.210 |
Why?
|
| Bilirubin | 6 | 2024 | 131 | 0.210 |
Why?
|
| T-Lymphocytes | 9 | 2012 | 1814 | 0.210 |
Why?
|
| Hepatitis B Surface Antigens | 7 | 2012 | 54 | 0.200 |
Why?
|
| Hepatitis B Antigens | 4 | 2010 | 10 | 0.200 |
Why?
|
| Deoxycytidine | 2 | 2013 | 84 | 0.200 |
Why?
|
| Transaminases | 3 | 2022 | 36 | 0.200 |
Why?
|
| Antibodies, Antinuclear | 2 | 2019 | 31 | 0.200 |
Why?
|
| Liver Neoplasms | 7 | 2014 | 1411 | 0.200 |
Why?
|
| Sex Factors | 2 | 2018 | 1383 | 0.200 |
Why?
|
| Immunization | 2 | 2024 | 315 | 0.200 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 319 | 0.200 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 755 | 0.190 |
Why?
|
| Data Collection | 1 | 2024 | 397 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2021 | 139 | 0.190 |
Why?
|
| Plasma Cells | 1 | 2022 | 57 | 0.190 |
Why?
|
| Graft Survival | 6 | 2021 | 558 | 0.190 |
Why?
|
| Treatment Failure | 4 | 2018 | 364 | 0.180 |
Why?
|
| Disease Progression | 6 | 2022 | 2242 | 0.180 |
Why?
|
| Valine | 6 | 2018 | 116 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2018 | 77 | 0.180 |
Why?
|
| Donor Selection | 2 | 2019 | 58 | 0.180 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 689 | 0.180 |
Why?
|
| Gilbert Disease | 4 | 2013 | 5 | 0.180 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1992 | 136 | 0.180 |
Why?
|
| HLA Antigens | 4 | 2016 | 253 | 0.180 |
Why?
|
| Transplantation, Homologous | 6 | 2007 | 693 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1850 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2005 | 749 | 0.170 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2017 | 34 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 6 | 2011 | 1079 | 0.170 |
Why?
|
| Cystic Fibrosis | 3 | 2020 | 264 | 0.170 |
Why?
|
| Fibrosis | 1 | 2022 | 461 | 0.170 |
Why?
|
| Tacrolimus | 5 | 2021 | 107 | 0.170 |
Why?
|
| Neoplasms | 7 | 2020 | 3027 | 0.170 |
Why?
|
| Waiting Lists | 4 | 2020 | 244 | 0.170 |
Why?
|
| Follow-Up Studies | 9 | 2025 | 5511 | 0.160 |
Why?
|
| Learning Curve | 1 | 2020 | 57 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2018 | 3699 | 0.160 |
Why?
|
| Transplantation | 1 | 2019 | 27 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 822 | 0.160 |
Why?
|
| Health Facilities | 1 | 2019 | 67 | 0.160 |
Why?
|
| Allografts | 4 | 2021 | 197 | 0.150 |
Why?
|
| Drug Combinations | 5 | 2018 | 283 | 0.150 |
Why?
|
| Protease Inhibitors | 3 | 2017 | 100 | 0.150 |
Why?
|
| Administration, Oral | 5 | 2024 | 730 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1991 | 358 | 0.150 |
Why?
|
| Vaccination | 1 | 2024 | 1011 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 866 | 0.150 |
Why?
|
| Inflammation | 2 | 2022 | 1599 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 757 | 0.140 |
Why?
|
| Immunization, Passive | 4 | 2000 | 128 | 0.140 |
Why?
|
| Spleen | 4 | 2011 | 291 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2013 | 319 | 0.140 |
Why?
|
| Uridine | 1 | 2017 | 36 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2014 | 1000 | 0.140 |
Why?
|
| Survival Rate | 4 | 2019 | 2210 | 0.140 |
Why?
|
| Sustained Virologic Response | 4 | 2018 | 46 | 0.140 |
Why?
|
| Macrocyclic Compounds | 1 | 2017 | 12 | 0.140 |
Why?
|
| Suicide | 1 | 2020 | 200 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 734 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1994 | 45 | 0.130 |
Why?
|
| Animals | 26 | 2024 | 36387 | 0.130 |
Why?
|
| Narcotics | 1 | 2017 | 64 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2018 | 136 | 0.130 |
Why?
|
| Glycerol | 2 | 2014 | 99 | 0.130 |
Why?
|
| Biological Products | 1 | 2019 | 137 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 295 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2024 | 1735 | 0.130 |
Why?
|
| Phenylbutyrates | 2 | 2014 | 58 | 0.130 |
Why?
|
| Triazoles | 1 | 2017 | 142 | 0.130 |
Why?
|
| Acetaminophen | 2 | 2013 | 100 | 0.130 |
Why?
|
| Prevalence | 2 | 2022 | 2654 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 1070 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2020 | 335 | 0.120 |
Why?
|
| Creatinine | 1 | 2018 | 429 | 0.120 |
Why?
|
| Bile Duct Diseases | 2 | 1993 | 17 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2014 | 467 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2020 | 184 | 0.120 |
Why?
|
| Incidence | 3 | 2025 | 3402 | 0.120 |
Why?
|
| Fasting | 2 | 2015 | 311 | 0.120 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 18 | 0.120 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2012 | 14 | 0.120 |
Why?
|
| Glutamine | 2 | 2014 | 222 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2015 | 99 | 0.120 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 1995 | 4 | 0.120 |
Why?
|
| Geography | 1 | 2015 | 124 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 318 | 0.120 |
Why?
|
| Quality of Life | 6 | 2021 | 2143 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 61 | 0.120 |
Why?
|
| Cytokines | 4 | 2011 | 1396 | 0.120 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 110 | 0.120 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1994 | 24 | 0.120 |
Why?
|
| Lactams | 1 | 2014 | 21 | 0.110 |
Why?
|
| Confidentiality | 1 | 2015 | 106 | 0.110 |
Why?
|
| Congresses as Topic | 3 | 2023 | 187 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 262 | 0.110 |
Why?
|
| Ritonavir | 1 | 2014 | 48 | 0.110 |
Why?
|
| Thioguanine | 2 | 2004 | 22 | 0.110 |
Why?
|
| Secondary Prevention | 4 | 2000 | 225 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 13 | 0.110 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2014 | 19 | 0.110 |
Why?
|
| Metabolomics | 1 | 2017 | 456 | 0.110 |
Why?
|
| Indoles | 1 | 2015 | 201 | 0.110 |
Why?
|
| Phenylacetates | 1 | 2013 | 23 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 40 | 0.110 |
Why?
|
| Chronic Disease | 8 | 1999 | 1254 | 0.110 |
Why?
|
| Acute Disease | 4 | 2025 | 1191 | 0.110 |
Why?
|
| Hyperammonemia | 1 | 2014 | 63 | 0.110 |
Why?
|
| Cell Movement | 2 | 2005 | 916 | 0.110 |
Why?
|
| Postoperative Complications | 5 | 2020 | 3227 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 1977 | 0.110 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 7212 | 0.100 |
Why?
|
| Autoimmunity | 2 | 2024 | 182 | 0.100 |
Why?
|
| Minor Histocompatibility Loci | 2 | 1991 | 2 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 1206 | 0.100 |
Why?
|
| Liver Function Tests | 6 | 2020 | 107 | 0.100 |
Why?
|
| Uridine Monophosphate | 1 | 2013 | 9 | 0.100 |
Why?
|
| Caffeine | 1 | 2013 | 71 | 0.100 |
Why?
|
| Azathioprine | 3 | 2018 | 56 | 0.100 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1993 | 122 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2007 | 2163 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 77 | 0.100 |
Why?
|
| Liver, Artificial | 2 | 2011 | 9 | 0.100 |
Why?
|
| Medical Futility | 1 | 2013 | 38 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 197 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 3 | 2018 | 19 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 196 | 0.100 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2013 | 85 | 0.100 |
Why?
|
| Time Factors | 11 | 2019 | 6590 | 0.100 |
Why?
|
| RNA Probes | 1 | 1992 | 31 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1195 | 0.100 |
Why?
|
| United States | 11 | 2017 | 11687 | 0.100 |
Why?
|
| Child | 14 | 2021 | 25739 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 352 | 0.100 |
Why?
|
| Lamivudine | 2 | 2002 | 27 | 0.100 |
Why?
|
| Aspirin | 1 | 2013 | 231 | 0.100 |
Why?
|
| Lymphocyte Activation | 3 | 2011 | 724 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 63 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 1984 | 494 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1382 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 1908 | 0.090 |
Why?
|
| Cyclophilins | 1 | 2011 | 20 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 412 | 0.090 |
Why?
|
| Hepatitis C Antibodies | 2 | 2010 | 24 | 0.090 |
Why?
|
| Mice | 10 | 2011 | 18909 | 0.090 |
Why?
|
| Contraindications | 2 | 2006 | 81 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 298 | 0.090 |
Why?
|
| Rituximab | 3 | 2020 | 164 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 1992 | 254 | 0.090 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 146 | 0.090 |
Why?
|
| Self Tolerance | 1 | 2011 | 6 | 0.090 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2011 | 39 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 65 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 169 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 542 | 0.090 |
Why?
|
| Base Sequence | 5 | 1998 | 3170 | 0.090 |
Why?
|
| Immune Tolerance | 2 | 2007 | 158 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2012 | 2902 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1417 | 0.090 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2008 | 58 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2296 | 0.080 |
Why?
|
| Chemokines | 1 | 2011 | 138 | 0.080 |
Why?
|
| Viral Structural Proteins | 1 | 1990 | 48 | 0.080 |
Why?
|
| Rats | 7 | 2008 | 3883 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 2 | 2011 | 621 | 0.080 |
Why?
|
| Budesonide | 2 | 2016 | 21 | 0.080 |
Why?
|
| Molecular Sequence Data | 5 | 1998 | 3967 | 0.080 |
Why?
|
| Genes, Viral | 1 | 1990 | 186 | 0.080 |
Why?
|
| Mycophenolic Acid | 2 | 2016 | 52 | 0.080 |
Why?
|
| Crohn Disease | 2 | 2004 | 287 | 0.080 |
Why?
|
| Copper | 2 | 1981 | 75 | 0.080 |
Why?
|
| Remission Induction | 4 | 2018 | 308 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2004 | 327 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 4777 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2013 | 282 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 268 | 0.080 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 218 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 320 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1890 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 550 | 0.080 |
Why?
|
| Age Factors | 1 | 2015 | 2979 | 0.070 |
Why?
|
| Trans-Activators | 1 | 1992 | 830 | 0.070 |
Why?
|
| Interferon-gamma | 3 | 1999 | 538 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 68 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 479 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 444 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 83 | 0.070 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 7 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1326 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2011 | 448 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 506 | 0.070 |
Why?
|
| United Kingdom | 2 | 2019 | 240 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1981 | 277 | 0.070 |
Why?
|
| Chylous Ascites | 1 | 1987 | 11 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1070 | 0.070 |
Why?
|
| Hyperbilirubinemia, Hereditary | 3 | 1982 | 3 | 0.070 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 1987 | 2 | 0.070 |
Why?
|
| Insemination, Artificial | 1 | 1987 | 13 | 0.070 |
Why?
|
| Texas | 2 | 2021 | 3689 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 1987 | 31 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3475 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 116 | 0.070 |
Why?
|
| Prednisolone | 2 | 2018 | 75 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 679 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 809 | 0.070 |
Why?
|
| Policy Making | 1 | 2007 | 62 | 0.070 |
Why?
|
| Abdomen | 1 | 1987 | 134 | 0.060 |
Why?
|
| Mitogens | 3 | 1992 | 32 | 0.060 |
Why?
|
| Leucine | 2 | 2018 | 313 | 0.060 |
Why?
|
| Immunity, Cellular | 2 | 2005 | 217 | 0.060 |
Why?
|
| Macrophages | 1 | 1991 | 704 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1999 | 149 | 0.060 |
Why?
|
| Cell Separation | 3 | 1992 | 234 | 0.060 |
Why?
|
| Epoprostenol | 1 | 2006 | 71 | 0.060 |
Why?
|
| Skin Diseases | 1 | 1987 | 135 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 1999 | 3167 | 0.060 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2005 | 39 | 0.060 |
Why?
|
| Puerto Rico | 2 | 2016 | 51 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 430 | 0.060 |
Why?
|
| Risk Management | 1 | 2005 | 70 | 0.060 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2004 | 6 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2005 | 465 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2007 | 407 | 0.060 |
Why?
|
| 1-Naphthylisothiocyanate | 1 | 2004 | 2 | 0.060 |
Why?
|
| Disease Management | 2 | 2020 | 561 | 0.060 |
Why?
|
| Hepatectomy | 1 | 2005 | 124 | 0.060 |
Why?
|
| RNAi Therapeutics | 1 | 2024 | 17 | 0.060 |
Why?
|
| Coinfection | 2 | 2018 | 182 | 0.060 |
Why?
|
| Nausea | 2 | 2017 | 86 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 40 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2022 | 6664 | 0.060 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 1997 | 59 | 0.060 |
Why?
|
| Microscopy, Electron | 4 | 2004 | 374 | 0.060 |
Why?
|
| Hepatitis A | 2 | 2013 | 32 | 0.050 |
Why?
|
| Retreatment | 2 | 2016 | 92 | 0.050 |
Why?
|
| Drug Carriers | 2 | 2015 | 118 | 0.050 |
Why?
|
| Transferrins | 1 | 2023 | 2 | 0.050 |
Why?
|
| Muromonab-CD3 | 1 | 2003 | 10 | 0.050 |
Why?
|
| Hemochromatosis Protein | 1 | 2023 | 23 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2006 | 213 | 0.050 |
Why?
|
| Hepcidins | 1 | 2023 | 27 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 232 | 0.050 |
Why?
|
| Nitrofurantoin | 1 | 2023 | 8 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1910 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 408 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 109 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2023 | 31 | 0.050 |
Why?
|
| Piperazines | 1 | 2005 | 257 | 0.050 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2002 | 8 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2024 | 145 | 0.050 |
Why?
|
| In Vitro Techniques | 3 | 1992 | 991 | 0.050 |
Why?
|
| Cholic Acids | 1 | 1982 | 16 | 0.050 |
Why?
|
| Ceruloplasmin | 2 | 1981 | 15 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 200 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2019 | 397 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 607 | 0.050 |
Why?
|
| Sirolimus | 1 | 2004 | 253 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2011 | 14800 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 714 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1994 | 911 | 0.050 |
Why?
|
| Gastroenterology | 1 | 2005 | 211 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1407 | 0.050 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2001 | 7 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 2 | 1992 | 57 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 2656 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2008 | 2539 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 390 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2002 | 148 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1315 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2005 | 417 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 259 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 275 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 48 | 0.040 |
Why?
|
| Infant | 5 | 2011 | 13161 | 0.040 |
Why?
|
| Isoantigens | 2 | 1992 | 25 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 3739 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1992 | 215 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2014 | 5182 | 0.040 |
Why?
|
| Iron | 1 | 2023 | 303 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2015 | 279 | 0.040 |
Why?
|
| Lymphocytes | 3 | 1980 | 440 | 0.040 |
Why?
|
| Monocytes | 3 | 1992 | 361 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 1736 | 0.040 |
Why?
|
| Hepatitis Antigens | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 417 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 181 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 398 | 0.040 |
Why?
|
| Methotrexate | 1 | 2002 | 355 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1999 | 12 | 0.040 |
Why?
|
| Hepatitis B Vaccines | 1 | 2000 | 45 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 341 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 20 | 0.040 |
Why?
|
| Carbonic Anhydrases | 1 | 1999 | 26 | 0.040 |
Why?
|
| Epidemics | 1 | 2020 | 59 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 766 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 567 | 0.040 |
Why?
|
| Abatacept | 1 | 2019 | 24 | 0.040 |
Why?
|
| Asialoglycoprotein Receptor | 3 | 1984 | 5 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 3056 | 0.040 |
Why?
|
| Transfection | 2 | 1992 | 1089 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 1999 | 99 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 52 | 0.040 |
Why?
|
| Epithelium | 2 | 1993 | 370 | 0.040 |
Why?
|
| Orosomucoid | 1 | 1978 | 9 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 225 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1998 | 24 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 1999 | 196 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 129 | 0.040 |
Why?
|
| Radioisotopes | 1 | 1978 | 37 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2001 | 325 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2018 | 26 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 1998 | 376 | 0.040 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1978 | 35 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8591 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 224 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2000 | 310 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.030 |
Why?
|
| Medicaid | 1 | 2000 | 254 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 162 | 0.030 |
Why?
|
| Thiazoles | 1 | 2017 | 102 | 0.030 |
Why?
|
| Taiwan | 1 | 2016 | 62 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1998 | 261 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1996 | 21 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 2004 | 260 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 504 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 127 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 407 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 239 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 156 | 0.030 |
Why?
|
| Medicare | 1 | 2000 | 465 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 1995 | 3 | 0.030 |
Why?
|
| Morbidity | 1 | 1997 | 255 | 0.030 |
Why?
|
| Rifamycins | 1 | 2016 | 21 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 293 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 823 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1761 | 0.030 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 1995 | 10 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2015 | 119 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 2 | 2002 | 13 | 0.030 |
Why?
|
| Portal Vein | 1 | 1995 | 95 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 341 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2017 | 203 | 0.030 |
Why?
|
| Nutrition Surveys | 2 | 2007 | 312 | 0.030 |
Why?
|
| Isoindoles | 1 | 2014 | 4 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 917 | 0.030 |
Why?
|
| Hepatitis D | 1 | 1994 | 3 | 0.030 |
Why?
|
| Hepatitis E virus | 1 | 1994 | 4 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 1994 | 6 | 0.030 |
Why?
|
| Hepatitis E | 1 | 1994 | 5 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 11 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1995 | 47 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 168 | 0.030 |
Why?
|
| Hepatovirus | 1 | 1994 | 17 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 100 | 0.030 |
Why?
|
| Ligases | 1 | 1994 | 48 | 0.030 |
Why?
|
| Quality Control | 1 | 1994 | 127 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 338 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1984 | 236 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1994 | 80 | 0.030 |
Why?
|
| Mitochondria | 1 | 1999 | 746 | 0.030 |
Why?
|
| Patient Preference | 1 | 2015 | 135 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1994 | 397 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 1993 | 9 | 0.030 |
Why?
|
| Magnesium Chloride | 1 | 1993 | 3 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1994 | 247 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1993 | 46 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 187 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 538 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2006 | 372 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1993 | 33 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 163 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1995 | 440 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 697 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 98 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2014 | 118 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 179 | 0.030 |
Why?
|
| Reoperation | 1 | 1997 | 866 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1242 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 239 | 0.030 |
Why?
|
| Bile | 2 | 2004 | 47 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1993 | 91 | 0.030 |
Why?
|
| Necrosis | 1 | 1993 | 220 | 0.030 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1992 | 39 | 0.030 |
Why?
|
| Proteins | 1 | 1978 | 1087 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 213 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1997 | 489 | 0.020 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1992 | 4 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 344 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 270 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 240 | 0.020 |
Why?
|
| Antibodies | 2 | 1992 | 382 | 0.020 |
Why?
|
| Indomethacin | 1 | 1992 | 86 | 0.020 |
Why?
|
| Virus Replication | 1 | 1995 | 638 | 0.020 |
Why?
|
| Genes | 1 | 1992 | 450 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 90 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 239 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1992 | 113 | 0.020 |
Why?
|
| Introns | 1 | 1992 | 313 | 0.020 |
Why?
|
| Lymphocytes, Null | 1 | 1991 | 2 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1139 | 0.020 |
Why?
|
| Plastics | 1 | 1991 | 15 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 342 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1991 | 109 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 1102 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1992 | 360 | 0.020 |
Why?
|
| Cell Membrane | 3 | 1984 | 486 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 455 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 295 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 321 | 0.020 |
Why?
|
| Cell Division | 1 | 1992 | 774 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1484 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1990 | 62 | 0.020 |
Why?
|
| Ischemia | 1 | 1993 | 383 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1990 | 133 | 0.020 |
Why?
|
| Autoradiography | 1 | 1989 | 74 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2002 | 4899 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1995 | 513 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 433 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1993 | 453 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2007 | 3639 | 0.020 |
Why?
|
| Fatigue | 1 | 2010 | 203 | 0.020 |
Why?
|
| Indocyanine Green | 2 | 1982 | 63 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1989 | 444 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2008 | 109 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 137 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 77 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1990 | 836 | 0.020 |
Why?
|
| Epitopes | 1 | 1989 | 446 | 0.020 |
Why?
|
| Peritoneum | 1 | 1987 | 40 | 0.020 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1990 | 239 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 1757 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 351 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2007 | 38 | 0.020 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2006 | 12 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2196 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 52 | 0.020 |
Why?
|
| Government Regulation | 1 | 2007 | 43 | 0.020 |
Why?
|
| Semen | 1 | 1987 | 79 | 0.020 |
Why?
|
| Kupffer Cells | 2 | 1984 | 22 | 0.020 |
Why?
|
| Social Justice | 1 | 2007 | 65 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 99 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1985 | 7 | 0.020 |
Why?
|
| Bile Canaliculi | 1 | 1985 | 4 | 0.020 |
Why?
|
| Basement Membrane | 1 | 1985 | 49 | 0.020 |
Why?
|
| Microvilli | 1 | 1985 | 72 | 0.020 |
Why?
|
| California | 1 | 2006 | 142 | 0.020 |
Why?
|
| Reproductive Medicine | 1 | 2005 | 20 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1990 | 922 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2006 | 3989 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2006 | 121 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1987 | 397 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 50 | 0.010 |
Why?
|
| Anthropometry | 1 | 2005 | 202 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2002 | 1484 | 0.010 |
Why?
|
| Medical Records | 1 | 2005 | 193 | 0.010 |
Why?
|
| Demography | 1 | 2005 | 247 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 570 | 0.010 |
Why?
|
| Sulfobromophthalein | 2 | 1982 | 3 | 0.010 |
Why?
|
| Cell Line | 1 | 1990 | 2836 | 0.010 |
Why?
|
| Hydroxyproline | 1 | 2004 | 7 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 604 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1984 | 96 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1984 | 260 | 0.010 |
Why?
|
| Benzamides | 1 | 2005 | 125 | 0.010 |
Why?
|
| Immune Sera | 1 | 1984 | 95 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2005 | 416 | 0.010 |
Why?
|
| Rabbits | 3 | 1980 | 736 | 0.010 |
Why?
|
| Mutation | 1 | 1998 | 6296 | 0.010 |
Why?
|
| Endothelium | 1 | 1984 | 71 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1984 | 206 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 1984 | 228 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1984 | 141 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 815 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 3850 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 1489 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 203 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 2002 | 5 | 0.010 |
Why?
|
| Mononuclear Phagocyte System | 2 | 1981 | 9 | 0.010 |
Why?
|
| Lysosomes | 1 | 1984 | 262 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 454 | 0.010 |
Why?
|
| Carrier Proteins | 2 | 1985 | 1066 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1982 | 111 | 0.010 |
Why?
|
| Kinetics | 2 | 1982 | 1355 | 0.010 |
Why?
|
| Penicillamine | 1 | 1981 | 6 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1983 | 261 | 0.010 |
Why?
|
| Mesalamine | 1 | 2001 | 6 | 0.010 |
Why?
|
| Neutrophils | 1 | 2004 | 401 | 0.010 |
Why?
|
| Spherocytosis, Hereditary | 1 | 1981 | 8 | 0.010 |
Why?
|
| Thyroxine | 1 | 1981 | 75 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1532 | 0.010 |
Why?
|
| Splenectomy | 1 | 1981 | 63 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1981 | 400 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1983 | 237 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1981 | 193 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 132 | 0.010 |
Why?
|
| Reference Values | 1 | 1982 | 742 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1411 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1335 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 1713 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1979 | 40 | 0.010 |
Why?
|
| Estrogens | 1 | 1981 | 522 | 0.010 |
Why?
|
| Complement C3b | 1 | 1978 | 7 | 0.010 |
Why?
|
| Animal Rights | 1 | 1998 | 1 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1998 | 51 | 0.010 |
Why?
|
| Haplorhini | 1 | 1998 | 121 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1998 | 28 | 0.010 |
Why?
|
| Surface Properties | 1 | 1978 | 95 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1998 | 27 | 0.010 |
Why?
|
| Vascular Fistula | 1 | 1998 | 31 | 0.010 |
Why?
|
| Prednisone | 1 | 1999 | 289 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 264 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1977 | 26 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1977 | 23 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1977 | 22 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1977 | 16 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1978 | 254 | 0.010 |
Why?
|
| Trypsin | 1 | 1977 | 95 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1998 | 125 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1998 | 175 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1977 | 31 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1977 | 33 | 0.010 |
Why?
|
| Temperance | 1 | 1997 | 15 | 0.010 |
Why?
|
| Homeostasis | 1 | 1981 | 746 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 799 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1998 | 244 | 0.010 |
Why?
|
| Echocardiography | 1 | 2002 | 1124 | 0.010 |
Why?
|
| Consciousness | 1 | 1997 | 49 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 33 | 0.010 |
Why?
|
| Eosinophils | 1 | 1997 | 128 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1998 | 202 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1999 | 406 | 0.010 |
Why?
|
| Testosterone | 1 | 1981 | 596 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 3981 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 21 | 0.010 |
Why?
|
| Intracranial Pressure | 1 | 1997 | 212 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1998 | 403 | 0.010 |
Why?
|
| Equipment Design | 1 | 1997 | 613 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1995 | 454 | 0.010 |
Why?
|
| Alcoholism | 1 | 1997 | 249 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1997 | 387 | 0.010 |
Why?
|
| Diet | 1 | 1981 | 1196 | 0.010 |
Why?
|
| Protein Binding | 1 | 1978 | 1832 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1046 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 2781 | 0.010 |
Why?
|
| Swine | 1 | 1997 | 1216 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 826 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1997 | 868 | 0.010 |
Why?
|
| Comorbidity | 1 | 1997 | 1617 | 0.010 |
Why?
|
| Biological Transport | 2 | 1979 | 369 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1981 | 34 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1981 | 67 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1981 | 34 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1981 | 61 | 0.000 |
Why?
|
| Antigens | 1 | 1981 | 157 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1981 | 119 | 0.000 |
Why?
|
| Chromium Radioisotopes | 1 | 1980 | 5 | 0.000 |
Why?
|
| Receptors, Fc | 1 | 1980 | 33 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1981 | 278 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1980 | 100 | 0.000 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1980 | 65 | 0.000 |
Why?
|
| Galactose | 1 | 1980 | 57 | 0.000 |
Why?
|
| Receptors, Complement | 1 | 1980 | 33 | 0.000 |
Why?
|
| Neuraminidase | 1 | 1980 | 39 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1981 | 357 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1979 | 70 | 0.000 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1978 | 41 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1978 | 145 | 0.000 |
Why?
|
| Glucagon | 1 | 1979 | 184 | 0.000 |
Why?
|
| Hematinics | 1 | 1979 | 60 | 0.000 |
Why?
|
| Lipoproteins | 1 | 1979 | 192 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1979 | 379 | 0.000 |
Why?
|
| Glucuronosyltransferase | 1 | 1976 | 72 | 0.000 |
Why?
|
| Binding Sites | 1 | 1978 | 1370 | 0.000 |
Why?
|